TEVA logo

Teva Pharmaceutical Industries Limited

TEVA
Healthcare|Drug Manufacturers - Specialty & Generic|IL
$42.61
+0.83 (+1.99%)
DCF Value
$18.62
Graham Number
$8.17
Cash / Share
$3.50
Next Earnings Report
Jan 27, 2027
EPS est. $0.69 · Revenue est. $4.26B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Sep 11, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Nov 3, 2026 · GlobeNewsWire
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Oct 27, 2026 · GlobeNewsWire
Teva to Host R&D Day on Wednesday, November 11 in New York City
Oct 12, 2026 · GlobeNewsWire
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Oct 9, 2026 · GlobeNewsWire
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
Oct 2, 2026 · GlobeNewsWire
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
Oct 2, 2026 · GlobeNewsWire
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
Oct 1, 2026 · Business Wire
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Sep 30, 2026 · GlobeNewsWire
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Sep 28, 2026 · GlobeNewsWire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Sep 23, 2026 · GlobeNewsWire

SEC Filings (57)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 3, 20268-KMaterial eventDocumentIndex
Nov 2, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-A12B/ADocumentIndex
Sep 14, 202625-NSEDocumentIndex
Sep 11, 2026424B5Offering prospectusDocumentIndex
Sep 11, 20268-KMaterial eventDocumentIndex
Sep 10, 2026FWPDocumentIndex
Sep 10, 2026FWPDocumentIndex
Sep 8, 2026424B5Offering prospectusDocumentIndex
Sep 3, 20268-KMaterial eventDocumentIndex
Sep 3, 20268-KMaterial eventDocumentIndex
Jul 29, 2026F-6 POSDocumentIndex
Jul 29, 202610-QQuarterly reportDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
May 28, 20268-KMaterial eventDocumentIndex
Apr 29, 202610-QQuarterly reportDocumentIndex
Apr 29, 20268-KMaterial eventDocumentIndex
Mar 31, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 31, 2026ARSAnnual report to holdersDocumentIndex
Mar 31, 2026DEF 14AProxy / shareholder voteDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 9, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 3, 202610-KAnnual reportDocumentIndex
Jan 28, 20268-KMaterial eventDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 11, 20258-KMaterial eventDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Oct 6, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 30, 202510-QQuarterly reportDocumentIndex
Jul 30, 20258-KMaterial eventDocumentIndex
Jul 22, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jul 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jun 5, 20258-KMaterial eventDocumentIndex